{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:24:42Z","timestamp":1790112282292,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":1130,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1111\/jth.14541","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T05:55:32Z","timestamp":1560923732000},"page":"1670-1682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-8964","authenticated-orcid":false,"given":"Virginie","family":"Siguret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Abdoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7134-0713","authenticated-orcid":false,"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Curis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe\u2010Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Gaussem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Funck\u2010Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Anne","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gouin\u2010Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14541_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/fcp.12091","article-title":"Pharmacology and mechanisms of action of new oral anticoagulants","volume":"29","author":"Salem","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1111\/jth.14541_bb0015","unstructured":"Bayer (Pharma AG). Xarelto\u00ae (rivaroxaban) summary of product characteristics. 2019."},{"key":"10.1111\/jth.14541_bb0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jth.12798","article-title":"The balance of pro\u2010 and anticoagulant processes underlying thrombin generation","volume":"13","author":"Kremers","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59\u20107939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jth.14541_bb0035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once\u2010 and twice\u2010daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban\u2013an oral, direct factor Xa inhibitor\u2013in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.14541_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jcph.5","article-title":"The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban\u2013an oral, direct Factor Xa inhibitor","volume":"53","author":"Kubitza","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jth.14541_bb0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thromb J"},{"key":"10.1111\/jth.14541_bb0055","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1111\/jth.14541_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.14541_bb0065","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/MBC.0000000000000371","article-title":"Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?","volume":"26","author":"Freyburger","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14541_bb0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13577","article-title":"Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin","volume":"15","author":"Gouin\u2010Thibault","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0075","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high\u2010risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0080","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0091270007302952","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet\u2010induced thrombin generation and prothrombinase activity","volume":"47","author":"Graff","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jth.14541_bb0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH15-01-0061","article-title":"Peri\u2010procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X\u2010PLORER trial","volume":"114","author":"Vranckx","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0090","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14541_bb0095","doi-asserted-by":"crossref","first-page":"e3037","DOI":"10.1097\/MD.0000000000003037","article-title":"Comparative assessment of the anticoagulant activity of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation: a noninterventional study","volume":"95","author":"Tsantes","year":"2016","journal-title":"Medicine"},{"key":"10.1111\/jth.14541_bb0100","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/rth2.12044","article-title":"Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay","volume":"1","author":"Artang","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0105","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/jth.13801","article-title":"Dissociation between the pharmacokinetics and pharmacodynamics of once\u2010daily rivaroxaban and twice\u2010daily apixaban: a randomized crossover study","volume":"15","author":"Kreutz","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0110","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11239-017-1492-2","article-title":"Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement","volume":"43","author":"Helin","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.14541_bb0115","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/ijlh.12767","article-title":"Effect of rivaroxaban on thrombin generation in vivo. A study in obese patients","volume":"40","author":"Bertaggia\u2010Calderara","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.14541_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12959-015-0037-1","article-title":"Global assays and the management of oral anticoagulation","volume":"13","author":"Brinkman","year":"2015","journal-title":"Thromb J"},{"key":"10.1111\/jth.14541_bb0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.chest.2017.09.047","article-title":"Are screening tests reliable to rule out direct oral anticoagulant plasma levels at various thresholds (30, 50, or 100\u00a0ng\/ml) in emergency situations?","volume":"153","author":"Jabet","year":"2018","journal-title":"Chest"},{"key":"10.1111\/jth.14541_bb0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/EJA.0000000000000903","article-title":"Detection of direct oral factor Xa inhibitors anticoagulants by modified rotational thromboelastometry","volume":"36","author":"Pailleret","year":"2019","journal-title":"Eur J Anaesthesiol"},{"key":"10.1111\/jth.14541_bb0135","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1538-7836.2007.02429.x","article-title":"In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0140","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.thromres.2011.07.026","article-title":"In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux","volume":"129","author":"Samama","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14541_bb0145","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3324\/haematol.2012.073601","article-title":"Large inter\u2010individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation","volume":"98","author":"Bloemen","year":"2013","journal-title":"Haematologica"},{"key":"10.1111\/jth.14541_bb0150","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1309\/AJCPQ2NJD3PXFTUG","article-title":"Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay","volume":"143","author":"Morishima","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.14541_bb0155","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1160\/TH15-09-0699","article-title":"Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation","volume":"115","author":"Kremers","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0160","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.thromres.2015.03.032","article-title":"How the direct oral anticoagulant apixaban affects thrombin generation parameters","volume":"135","author":"Tripodi","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14541_bb0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/rth2.12048","article-title":"A review of commercially available thrombin generation assays","volume":"2","author":"Kintigh","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/jth.14541_bb0175","unstructured":"Siguret V, Foulon\u2010Pinto G, Abdoul J, Carlo A, Lecompte T, Gouin\u2010Thibault I. Thrombin generation analysis with a new automated system (ST\u2010Genesia): interseries performances during DRIVING study and comparison with CAT system. 64th Annual Scientific and Standardization Committee meeting \u2010 ISTH, Dublin, July 2018, Res Pract Thromb Haemost, PB584, p286."},{"key":"10.1111\/jth.14541_bb0180","unstructured":"Arus M, Vilalta N, Romero L, Tirado I, Llobet D, Vallv\u00e9 C, et\u00a0al. Comparison between the standard thrombin generation method and the automated thrombin generation technique. 2nd European Congress on Thrombosis and Haemostasis, Marseille, September 2018, Abstract book P217, p238."},{"key":"10.1111\/jth.14541_bb0185","unstructured":"Pinheiro J, Bates D, DebRoy S, Sarkar D; R Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1\u2010137, 2018."},{"key":"10.1111\/jth.14541_bb0190","series-title":"R: a language and environment for statistical computing","year":"2018"},{"key":"10.1111\/jth.14541_bb0195","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2014.12.015","article-title":"Large external quality assessment survery on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma","volume":"136","author":"Perrin","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14541_bb0200","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jth.12236","article-title":"In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban","volume":"11","author":"Dinkelaar","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0205","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jth.12591","article-title":"Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor\u2010induced hypercoagulability in vitro and in vivo","volume":"12","author":"Perzborn","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1111\/jth.14541_bb0210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/fcp.12259","article-title":"Analysis of temozolomide resistance in low\u2010grade gliomas using a mechanistic mathematical model","volume":"31","author":"Ollier","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1111\/jth.14541_bb0215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2009.07833.x","article-title":"Acquired coagulation disorders: revisited using global coagulation\/anticoagulation testing","volume":"147","author":"Tripodi","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14541_bb0220","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/AAP.0000000000000223","volume":"40","author":"Narouze","year":"2015","journal-title":"Reg Anesth Pain Med"},{"key":"10.1111\/jth.14541_bb0225","first-page":"73","article-title":"Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) \u2010 September 2015","volume":"36","author":"Albaladejo","year":"2017","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1111\/jth.14541_bb0230","doi-asserted-by":"crossref","first-page":"e0176967","DOI":"10.1371\/journal.pone.0176967","article-title":"Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing","volume":"12","author":"Bloemen","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.14541_bb0235","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1160\/TH05-10-0685","article-title":"Age\u2010dependency of thrombin generation measured by means of calibrated automated thrombography (CAT)","volume":"95","author":"Haidl","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0240","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1160\/TH06-03-0162","article-title":"Age\u2010dependency of thrombin generation","volume":"95","author":"Hemker","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14541_bb0245","series-title":"Computational toxicology: volume I","first-page":"583","article-title":"Mechanism\u2010based pharmacodynamic modeling","author":"Felmlee","year":"2012"},{"key":"10.1111\/jth.14541_bb0250","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti\u2010Factor Xa activity, and outcomes: an analysis of data from the randomised, double\u2010blind ENGAGE AF\u2010TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14541","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622033463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622033463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:25:14Z","timestamp":1761535514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622033463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1538783622033463"],"URL":"https:\/\/doi.org\/10.1111\/jth.14541","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}